Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19.

Chia Siang KowSyed Tabish Razi ZaidiSyed Shahzad Hasan

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2020)

There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.

Keyphrases

coronavirus disease
sars cov
cardiovascular disease
respiratory syndrome coronavirus
wild type
randomized controlled trial
metabolic syndrome
coronary artery disease
human health